Holen Sie sich die Stockscreener-App
28.02
0.07%
0.02
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpWhat's Next? - MarketBeat
Moody Aldrich Partners LLC Has $5.02 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Edgewise Therapeutics names new COO - MSN
Edgewise Therapeutics reshuffles executive team - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.1%Here's What Happened - MarketBeat
Edgewise elevates chief operating officer, hires development exec - BizWest
Edgewise Therapeutics Promotes Behrad Derakhshan, Ph.D., to Chief Operating Officer Role - Defense World
Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? - Insider Monkey
New COOs for Vividion, Edgewise - BioCentury
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownWhat's Next? - MarketBeat
Edgewise Therapeutics names new COO By Investing.com - Investing.com Australia
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - BioSpace
Edgewise Therapeutics (NASDAQ:EWTX) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan
Edgewise stock rated as a new Hold at Stifel (EWTX:NASDAQ) - Seeking Alpha
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target By Investing.com - Investing.com Canada
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Update - MarketBeat
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Should You Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 - Business Wire
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - BioSpace
How To Trade (EWTX) - Stock Traders Daily
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $2,737,000.00 in Stock - MarketBeat
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock - Investing.com India
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data (NASDAQ:EWTX) - Seeking Alpha
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):